chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Sweating in the palms of hands, forehead, extreme  out of body sense, diarrhea. EMS was contacted and patient had their vitals checked and then refused to go to be evaluated at hospital via ambulance 30 minutes later. A follow up call was made to patient 17 hours later for check up and patient reported she was a little tired but otherwise felt fine with no injection site pain to report. Pt did note she was experiencing discomfort in her collarbone no relation to immunization.
After 4 days of second shot. Fever 100, chills, nausea After two weeks, still having same effect
Patient received the Moderna Covid19 vaccine on 01/19/21. Customer then called pharmacy on 1/30/2021 to report to pharmacist that he had had redness and inflammation at the site of injection since he received the shot 11 days ago. He said that he went to see Dr. who is sending in an antibiotic prescription for his affected arm. Customer stated that MD thought he had developed cellulitis/ infection at the injection site. Customer picked up the antibiotic from the pharmacy on 1/30/2021.
Appendicitis. Perforated appendix that started 6 days after vaccination; This is a spontaneous report from a contactable consumer. A 38-year-old male consumer (patient) reported that he received BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number unknown) via an unspecified route of administration in left arm on 11Apr2021 10:00AM (at the age of 38-year-old) for COVID-19 immunisation. Relevant medical history and concomitant medications were not reported. The patient had not COVID prior vaccination. On 17Apr2021, the patient had perforated appendix that started 6 days after vaccination. The event resulted in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care, hospitalization, life threatening illness (immediate risk of death from the event). The patient was hospitalized for 6 days. Treatment included antibiotic and potential surgery upcoming. The patient was tested for COVID post vaccination (no results). The event was not resolved.  Information on the lot/batch number has been requested.
Patient presented to emergency department with nausea, diarrhea, fatigue, and body aches. Patient was given phenergan with resolution of symptoms. Patient was discharged home in stable condition
Call received from parent stating that her daughter experienced headache, nausea, vomiting, shaking chills and dizziness the evening after vaccination. Symptoms lasted all night into the next day when they visited her private physician for evaluation and physical. They are unsure if she was febrile during this time. Also stated that she was pale. Immediately after vaccination, c/o feeling dizzy and slight nausea. She was pale, BP 88/50 P56. After brief period of lying down,the symptoms subsided and she was allowed to leave the treatment area after 30 minutes with no further treatment required.
pt recvd vax;recvd 3rd dose & still tested neg for varicella on 24nov95;
Small vessel Vasculitis, Warmth, swelling, petechia of bilateral legs. Confirmed by biopsy with additional lab work. Resolved on appropriately doses steroids for 4 weeks.
Breakthrough case admission after 3 vaccines Pfizer 1/7/21 Lot# EL3246;  Pfizer 1/28/21 lot# EN5318;  Pfizer 10/7/21 lot# FF2590
Information has been received from a licensed practical nurse concerning a male patient with no known allergies or pertinent medical history who on an unspecified date was vaccinated IM with a first dose of 0.5ml of MMR II (lot # 657630/1483U). There was no concomitant medication. Subsequently, the patient had a negative rubella antibody titer on an unspecified date. At the time of the report the patient's status was unknown. There was no product quality complaint involved. Additional information has been requested.
Narrative:  Facility, Moderna x4, covid +, fall, weakness, confusion, cough, d/c home
I had an allergic reaction within ten minutes and was taken to the emergency room with throat pain, itching in the throat and mouth and a swollen uvula. I was given multiple doses of Benadryl and steroids. The next day I developed a temperature of 102 degrees and had a severe headache, nausea, and body aches. The headache and fatigue are still present now 4 days later.
(Less than 1 week after vaccines ) Death 3/23/08 - found dead in crib 3/23/08 AM by mother. Pronounced dead at the scene. Autopsy pending. Unknown if related to vaccines. 6/20/08-records received-final cause of death:Sudden Infant Death Syndrome. 6/20/08-autopsy report:findings included intrathoracic petechiae, umbilical hernia, tibial subperiosteal new bone formation and right hydrocele.
Developed suspected vaccinia lesions after exposure (wrestling) to individual who received smallpox vaccination for military.
not received the 2nd dose yet.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 67-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in 2021).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: not received the 2nd dose yet.).  The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 01-SEP-2023 The pharmacist called to inform that a patient that received the 1st dose of Shingrix in 2021 had not received the 2nd dose yet. The vaccine administration facility was the same as primary reporter. Till the time of reporting the patient did not receive 2nd dose, which led to incomplete course of vaccination. The reporter consented to follow up.
I felt a little sick the day after receiving the vaccine. On 11/17/2022 I was at physical therapy, and they said my blood pressure was low and they recommended that I keep an eye on it. I went to see my endocrinologist and had blood work and my cholesterol was higher than normal. My fitness watch indicated my resting heart rate was elevated. At this time, I am watching what I eat.
patient stated day after the vaccination, she experienced shaking , twitch like on the left arm (arm she received her vaccine) Patient did have pain at the injection site and swelling. Advise patient to take tylenol for pain. If shaking still continues or worsen, to seek (pcp) for help
Pt stated he was starting to feel light headed and then fainted, broke out in sweat, and became flushed.
malaise; Body aches; hot flashes; Reactions like chills; This case was reported by a consumer via call center representative and described the occurrence of malaise in a 61-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced malaise, general body pain, hot flashes and chills. The action taken with Shingrix was unknown. On an unknown date, the outcome of the malaise, general body pain, hot flashes and chills were recovered/resolved.   It was unknown if the reporter considered the malaise, general body pain, hot flashes and chills to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. After receiving 1st dose of Shingrix, the patient experianced chills, malaise, body aches, and hot flashes. The reporter was consented to follow up. For the tolerance of 2nd dose, refer linked case US2020AMR148511.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR148511:Same patient
6 patients received vaccine stored 32 days in refrigirator; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT STORAGE ERROR (6 patients received vaccine stored 32 days in refrigirator) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-May-2021, the patient experienced PRODUCT STORAGE ERROR (6 patients received vaccine stored 32 days in refrigirator). At the time of the report, PRODUCT STORAGE ERROR (6 patients received vaccine stored 32 days in refrigirator) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Most recent FOLLOW-UP information incorporated above includes: On 07-May-2021: Follow up received on 07-May-2021 and contains no new information
Pt vaccinated with HIB-titer 6 months post immunization, child dx w/ HIB disease. Fever of 105 and could not walk. Admitted to hosp w/Pneumonia, body rash & his eyes were swollen shut. Blood culture were + for HIB disease.
Under 12 years of age; date of birth 12/11/2009; no adverse symptoms
This spontaneous report as received from a nurse via a company representative and refers to a 65 year old male patient. The pertinent medical history of the patient included hypertension, atrial fibrillation, type 2 diabetes mellitus, prostate cancer and obesity. No information on the patient's concomitant medications and drug reactions or allergies was reported. The patient was vaccinated with the first dose of PNEUMOVAX 23 on 17-OCT-2002 for prophylaxis (dose, route of adminsitration, lot # and expiration date were not reported) and experienced no adverse events at that time. On 31-OCT-2018, the patient was vaccinated with the second dose of PNEUMOVAX 23 (lot # R012360, expiration date 15-JAN-2020) injection, 0.5 milliliter, once, intramuscularly in the left deltoid for prophylaxis to prevent pneumococcal disease. The patient had an appointment with cardiology on 01-NOV-2018, when it was noted that the patient had coughing and shortness of breath (it was not specified if the cardiology appointment was related to something that occurred after the PNEUMOVAX 23 was administration or not). The patient saw physician on 06-NOV-2018 and presented with shortness of breath, coughing and congested lungs. The patient was admitted to an unspecified hospital on 06-NOV-2018 and released on 08-NOV-2018. The outcome of the events was reported as recovered/resolved on unspecified date in November 2018. Causality relatedness was not reported. Upon internal review, the event of congested lungs was considered as medically significant.
Happened ~ 7 PM, lasted 3-5 min, full body seizure, called 911. No hx febrile sz Dad with hx febrile sz. When seizure started temp 102 - went up to 104. Gave ZYVOX for (R) arm told "red". D/C to home & for full next day. Dx with febrile seizure.
The patient missed their second scheduled Moderna COVID-19 dose/> 42 days since the first dose; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (The patient missed their second scheduled Moderna COVID-19 dose/> 42 days since the first dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (The patient missed their second scheduled Moderna COVID-19 dose/> 42 days since the first dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (The patient missed their second scheduled Moderna COVID-19 dose/> 42 days since the first dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medication was reported. Treatment information were not provided.    Reporter did not allow further contact
headache; high fever; chills; body aches; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (headache), PYREXIA (high fever), CHILLS (chills) and MYALGIA (body aches) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Jan-2021, the patient experienced HEADACHE (headache), PYREXIA (high fever), CHILLS (chills) and MYALGIA (body aches). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency and IBUPROFEN (MOTRIN [IBUPROFEN]) at an unspecified dose and frequency. On 30-Jan-2021, HEADACHE (headache), PYREXIA (high fever), CHILLS (chills) and MYALGIA (body aches) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Jan-2021, Body temperature: high (High) High.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Information has been received from a medical assistant concerning her 16 year old daughter with no medical history or known drug allergies who on 25-SEP-2006 was vaccinated with a first dose of Gardasil (lot # not specified). On 22-NOV-2006 the patient was vaccinated with a second dose of Gardasil (lot # not reported) and experienced fatigue and tiredness right after receiving the second dose, lasting approximately two days. On 22-MAR-2007 the patient was vaccinated with a third dose of Gardasil (lot # not specified) and experienced fatigue and tiredness right after receiving the third dose, lasting approximately two days. The patient slept all day after receiving the second and third doses. Subsequently, the patient recovered from fatigue and tiredness. The patient sought unspecified medical attention. A product quality device was not involved. Additional information has been requested.
Patient woke in the early morning of 4/7/21 to pain and swelling in the left arm at injection site. He states that the swollen area is hot, sore and hard. It woke him from his sleep and did not occur until over a week after his vaccination.
acoustic neuroma; right facial numbness; Shingles; Patient was diagnosed with trigeminal neuropathy; hearing loss; This initial spontaneous report was received on 06-DEC-2019, from a lawyer regarding a case in litigation and refers to a female patient of unknown age. The patient's pertinent medical history, concurrent conditions or concomitant medications were not reported. On or around 21-SEP-2016, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) for routine health maintenance and its intended purpose: the prevention of shingles (herpes zoster) (the dosage regimen information was not reported). Shortly after vaccination, the patient suffered right sided facial numbness and blisters, the patient was diagnosed with trigeminal neuropathy and herpes zoster/shingles. Shortly after this episode, she started to experience facial numbness and hearing deficit of the right ear. The patient was hospitalized and diagnosed with acoustic neuroma, right facial numbness, and hearing loss of the right ear. As a direct and proximate result of zoster vaccine live (ZOSTAVAX) vaccination, the patient's symptoms had resulted in physical limitations not present prior to vaccination. She also experienced mental and emotional distress due to resulting physical limitations and seriousness of her condition, severe, serious, incurable, progressive and permanent personal injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of patient's vaccination, she had suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. At the time of the report, the patient's outcome was not recovered. The adverse events were considered as medically significant by the reporter as they were serious.
I have had tinnitus since March 28 after receiving my second dose of Moderna on March 26 I went to audiologist to test hearing and check ear structure resulting in minimal hearing loss diagnosis.  Audiologist stated that it was a brain issue not an ear issue so there is no treatment.
Redness in her upper arm; Inflamation in the injection area; Rash in her arm; Slight inflamation; This spontaneous case was reported by a consumer and describes the occurrence of INFLAMMATION (Slight inflamation), ERYTHEMA (Redness in her upper arm), VACCINATION SITE INFLAMMATION (Inflamation in the injection area) and RASH (Rash in her arm) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006D21A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 ml. On 18-Mar-2021, the patient experienced INFLAMMATION (Slight inflamation). On 26-Mar-2021, the patient experienced ERYTHEMA (Redness in her upper arm), VACCINATION SITE INFLAMMATION (Inflamation in the injection area) and RASH (Rash in her arm). At the time of the report, INFLAMMATION (Slight inflamation), ERYTHEMA (Redness in her upper arm), VACCINATION SITE INFLAMMATION (Inflamation in the injection area) and RASH (Rash in her arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
3-4 hours after vaccine patient broke out in a rash and a fever of 103. Went to Urgent Care and Tx with Antihistamine. Seen by Dr. 1/26/17. Dx Erythema Multiforme.
Left arm sore 1 hour after shot-tossed and turned at night.  Edismfen of muscle swollen on the day after shot-red, hot, arm and shoulder and back hurts.  Arrigin deltoid region-very red and hot.  Sent to MD.  Achy feeling "don't feel good" , redness tender to neck.  10/15/2003: Ill today.  Didn't see MD yesterday, just went home.  Today called MD and he was not in.  Has diarrhea today, still achy, has headache, arm very sore, still a little red but not "bright red" and dies non-extended up neck like yesterday.  Still planning on seeing MD to follow up with another MD if can't see primary MD. Denies illness prior to flu shot.  "I'm never sick".  10/16/2003: Back at work, feeling better now, arm not swollen, only a little pink, soreness much better.  Did not see MD at her own decision.
I had simple soreness on my arm where I received the vaccination on the first day. I woke up the next morning around 5 AM and had intense pain in the muscles in my upper left arm which made me unable to move it. I couldn?t even rotate my arm to look at my watch because the pain was so severe. Ibuprofen did not help relieve the pain. I also had flu-like symptoms and  others reported that my face and neck on the left side were slightly swollen.  The pain improved, but persisted. As I type into this form, I still have some limited mobility in my arm.
Around 1325 starting having chest pain and nausea. States pain is similar to heart burn and is constant.
This case was reported by a consumer via call center representative and described the occurrence of rash in a male patient who received SHINGRIX. On 9th March 2018, the patient received SHINGRIX (subcutaneous). On 9th March 2018, unknown after receiving SHINGRIX, the patient experienced intramuscular formulation administered by other route. In March 2018, the patient experienced rash and fever. On 14th March 2018, the outcome of the rash was recovered/resolved. In March 2018, the outcome of the fever was recovered/resolved. On an unknown date, the outcome of the intramuscular formulation administered by other route was unknown. It was unknown if the reporter considered the rash and fever to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient reported that at pharmacy the vaccine was accidently given to him to the back of his arm as a subcutaneous injection and not the side of his arm as an intramuscular injection, which led to intramuscular formulation administered by other route. The patient asked about the effects of SHINGRIX being administered in back of arm instead of intramuscular. The patient experienced experienced and 8 inch long by 2 inch wide rash. The patient also experienced a low-grade fever that lasted one day. The patient later went to a different pharmacy to show the pharmacist the rash. The pharmacist explained that the vaccine should have been given intramuscular (IM). The pharmacist who originally gave the vaccine did not know that the new vaccine was intramuscular.
1 st vaccine soreness in my arm lasted a day 2nd vaccine weak no appetite could not get out of the bed left leg swollen (size of both calls together)for 9 days. Skin continues to break out since second injection in hives swelling itching.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. No information was provided regarding concomitant medications, concurrent conditions or medical history. On or about 08-OCT-2010, the patient was inoculated with ZOSTAVAX as recommended for routine adult health maintenance for the prevention of shingles (strength, dose number, anatomical location, route of administration, lot number and expiration date were not reported). The vaccine did not prevent shingles as intended (vaccination failure) and the patient subsequently contracted a persistent strain condition of herpes zoster. On an unspecified date in 2014, the patient was treated for a onset of a severe vesicular rash, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering (emotional distress), and other damages. The outcome of the events was unknown. Causality assessment was related.